South Korean botulinum toxin makers gain U.S. share with prices 20-35% below premium brands
Daewoong's Jeuveau reached 14% U.S. market share last year, while Hugel targets 10% by 2028 as the U.S. toxin market is projected to grow to $11.53 billion by 2033.